Atomoxetine and Methylphenidate Treatment in Children with ADHD: A Prospective, Randomized, Open-Label Trial

Christopher J Kratochvil, John H. Heiligenstein, Ralf Dittmann, Thomas J. Spencer, Joseph Biederman, Joachim Wernicke, Jeffrey H. Newcorn, Charles Casat, Denái Milton, David Michelson

Research output: Contribution to journalArticle

265 Citations (Scopus)

Abstract

Objective: To assess the comparability of atomoxetine, a new therapy for attention-deficit/hyperactivity disorder (ADHD) and methylphenidate. (Atomoxetine was originally called tomoxetine. The name was recently changed in order to avoid any potential confusion with tamoxifen that might lead to errors in dispensing drug.) Method: Children with ADHD were randomized to open-label atomoxetine or methylphenidate for 10 weeks. Response was assessed with the ADHD-IV Rating Scale. Results: Two hundred twenty-eight patients were randomized (atomoxetine n = 184, methylphenidate n = 44). Both drugs were associated with marked improvement in inattentive and hyperactive-impulsive symptom clusters as assessed by parents and investigators. No statistically significant differences between treatment groups were observed on the primary outcome measure (investigator-rated ADHD-IV Rating Scale total score: atomoxetine baseline: 39.4 [8.5], endpoint: 20.0 [13.9]; methylphenidate baseline: 37.6 [9.7], endpoint: 19.8 (16.6); p =.66). Safety and tolerability were also similar between the 2 drugs. Discontinuations due to adverse events were 10/184 (5.4%) for atomoxetine and 5/44 (11.4%) for methylphenidate; p = .175. Conclusion: These data provide preliminary evidence that atomoxetine is associated with therapeutic effects comparable to those of methylphenidate.

Original languageEnglish (US)
Pages (from-to)776-784
Number of pages9
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume41
Issue number7
DOIs
StatePublished - Jul 2002

Fingerprint

Methylphenidate
Attention Deficit Disorder with Hyperactivity
Therapeutics
Research Personnel
Pharmaceutical Preparations
Atomoxetine Hydrochloride
Therapeutic Uses
Tamoxifen
Names
Parents
Outcome Assessment (Health Care)
Safety

Keywords

  • Atomoxetine
  • Attention-deficit/hyperactivity disorder
  • Children
  • Methylphenidate
  • Nonstimulants

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this

Atomoxetine and Methylphenidate Treatment in Children with ADHD : A Prospective, Randomized, Open-Label Trial. / Kratochvil, Christopher J; Heiligenstein, John H.; Dittmann, Ralf; Spencer, Thomas J.; Biederman, Joseph; Wernicke, Joachim; Newcorn, Jeffrey H.; Casat, Charles; Milton, Denái; Michelson, David.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 41, No. 7, 07.2002, p. 776-784.

Research output: Contribution to journalArticle

Kratochvil, CJ, Heiligenstein, JH, Dittmann, R, Spencer, TJ, Biederman, J, Wernicke, J, Newcorn, JH, Casat, C, Milton, D & Michelson, D 2002, 'Atomoxetine and Methylphenidate Treatment in Children with ADHD: A Prospective, Randomized, Open-Label Trial', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 41, no. 7, pp. 776-784. https://doi.org/10.1097/00004583-200207000-00008
Kratochvil, Christopher J ; Heiligenstein, John H. ; Dittmann, Ralf ; Spencer, Thomas J. ; Biederman, Joseph ; Wernicke, Joachim ; Newcorn, Jeffrey H. ; Casat, Charles ; Milton, Denái ; Michelson, David. / Atomoxetine and Methylphenidate Treatment in Children with ADHD : A Prospective, Randomized, Open-Label Trial. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2002 ; Vol. 41, No. 7. pp. 776-784.
@article{6a6b32ff6e894e48bd30c275c597e6c2,
title = "Atomoxetine and Methylphenidate Treatment in Children with ADHD: A Prospective, Randomized, Open-Label Trial",
abstract = "Objective: To assess the comparability of atomoxetine, a new therapy for attention-deficit/hyperactivity disorder (ADHD) and methylphenidate. (Atomoxetine was originally called tomoxetine. The name was recently changed in order to avoid any potential confusion with tamoxifen that might lead to errors in dispensing drug.) Method: Children with ADHD were randomized to open-label atomoxetine or methylphenidate for 10 weeks. Response was assessed with the ADHD-IV Rating Scale. Results: Two hundred twenty-eight patients were randomized (atomoxetine n = 184, methylphenidate n = 44). Both drugs were associated with marked improvement in inattentive and hyperactive-impulsive symptom clusters as assessed by parents and investigators. No statistically significant differences between treatment groups were observed on the primary outcome measure (investigator-rated ADHD-IV Rating Scale total score: atomoxetine baseline: 39.4 [8.5], endpoint: 20.0 [13.9]; methylphenidate baseline: 37.6 [9.7], endpoint: 19.8 (16.6); p =.66). Safety and tolerability were also similar between the 2 drugs. Discontinuations due to adverse events were 10/184 (5.4{\%}) for atomoxetine and 5/44 (11.4{\%}) for methylphenidate; p = .175. Conclusion: These data provide preliminary evidence that atomoxetine is associated with therapeutic effects comparable to those of methylphenidate.",
keywords = "Atomoxetine, Attention-deficit/hyperactivity disorder, Children, Methylphenidate, Nonstimulants",
author = "Kratochvil, {Christopher J} and Heiligenstein, {John H.} and Ralf Dittmann and Spencer, {Thomas J.} and Joseph Biederman and Joachim Wernicke and Newcorn, {Jeffrey H.} and Charles Casat and Den{\'a}i Milton and David Michelson",
year = "2002",
month = "7",
doi = "10.1097/00004583-200207000-00008",
language = "English (US)",
volume = "41",
pages = "776--784",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Atomoxetine and Methylphenidate Treatment in Children with ADHD

T2 - A Prospective, Randomized, Open-Label Trial

AU - Kratochvil, Christopher J

AU - Heiligenstein, John H.

AU - Dittmann, Ralf

AU - Spencer, Thomas J.

AU - Biederman, Joseph

AU - Wernicke, Joachim

AU - Newcorn, Jeffrey H.

AU - Casat, Charles

AU - Milton, Denái

AU - Michelson, David

PY - 2002/7

Y1 - 2002/7

N2 - Objective: To assess the comparability of atomoxetine, a new therapy for attention-deficit/hyperactivity disorder (ADHD) and methylphenidate. (Atomoxetine was originally called tomoxetine. The name was recently changed in order to avoid any potential confusion with tamoxifen that might lead to errors in dispensing drug.) Method: Children with ADHD were randomized to open-label atomoxetine or methylphenidate for 10 weeks. Response was assessed with the ADHD-IV Rating Scale. Results: Two hundred twenty-eight patients were randomized (atomoxetine n = 184, methylphenidate n = 44). Both drugs were associated with marked improvement in inattentive and hyperactive-impulsive symptom clusters as assessed by parents and investigators. No statistically significant differences between treatment groups were observed on the primary outcome measure (investigator-rated ADHD-IV Rating Scale total score: atomoxetine baseline: 39.4 [8.5], endpoint: 20.0 [13.9]; methylphenidate baseline: 37.6 [9.7], endpoint: 19.8 (16.6); p =.66). Safety and tolerability were also similar between the 2 drugs. Discontinuations due to adverse events were 10/184 (5.4%) for atomoxetine and 5/44 (11.4%) for methylphenidate; p = .175. Conclusion: These data provide preliminary evidence that atomoxetine is associated with therapeutic effects comparable to those of methylphenidate.

AB - Objective: To assess the comparability of atomoxetine, a new therapy for attention-deficit/hyperactivity disorder (ADHD) and methylphenidate. (Atomoxetine was originally called tomoxetine. The name was recently changed in order to avoid any potential confusion with tamoxifen that might lead to errors in dispensing drug.) Method: Children with ADHD were randomized to open-label atomoxetine or methylphenidate for 10 weeks. Response was assessed with the ADHD-IV Rating Scale. Results: Two hundred twenty-eight patients were randomized (atomoxetine n = 184, methylphenidate n = 44). Both drugs were associated with marked improvement in inattentive and hyperactive-impulsive symptom clusters as assessed by parents and investigators. No statistically significant differences between treatment groups were observed on the primary outcome measure (investigator-rated ADHD-IV Rating Scale total score: atomoxetine baseline: 39.4 [8.5], endpoint: 20.0 [13.9]; methylphenidate baseline: 37.6 [9.7], endpoint: 19.8 (16.6); p =.66). Safety and tolerability were also similar between the 2 drugs. Discontinuations due to adverse events were 10/184 (5.4%) for atomoxetine and 5/44 (11.4%) for methylphenidate; p = .175. Conclusion: These data provide preliminary evidence that atomoxetine is associated with therapeutic effects comparable to those of methylphenidate.

KW - Atomoxetine

KW - Attention-deficit/hyperactivity disorder

KW - Children

KW - Methylphenidate

KW - Nonstimulants

UR - http://www.scopus.com/inward/record.url?scp=0036633805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036633805&partnerID=8YFLogxK

U2 - 10.1097/00004583-200207000-00008

DO - 10.1097/00004583-200207000-00008

M3 - Article

C2 - 12108801

AN - SCOPUS:0036633805

VL - 41

SP - 776

EP - 784

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 7

ER -